Endoscopic features of low-grade dysplastic Barrett’s

Abstract

Background and study aims Barrett’s esophagus (BE) with low-grade dysplasia (LGD) is considered usually endoscopically invisible and the endoscopic features are not well described. This study aimed to: 1) evaluate the frequency of visible BE-LGD; 2) compare rates of BE-LGD detection in the community versus a Barrett’s referral unit (BRU); and 3) evaluate the endoscopic features of BE-LGD.

Patients and methods This was a retrospective analysis of a prospectively observed cohort of 497 patients referred to a BRU with dysplastic BE between 2008 and 2022. BE-LGD was defined as confirmation of LGD by expert gastrointestinal pathologist(s). Endoscopy reports, images and histology reports were reviewed to evaluate the frequency of endoscopically identifiable BE-LGD and their endoscopic features.

Results A total of 135 patients (27.2%) had confirmed BE-LGD, of whom 15 (11.1%) had visible LGD identified in the community. After BRU assessment, visible LGD was detected in 68 patients (50.4%). Three phenotypes were observed: (A) Non-visible LGD; (B) Elevated (Paris 0-IIa) lesions; and (C) Flat (Paris 0-IIb) lesions with abnormal mucosal and/or vascular patterns with clear demarcation from regular flat BE. The majority (64.7%) of visible LGD was flat lesions with abnormal mucosal and vascular patterns. Endoscopic detection of BE-LGD increased over time (38.7% (2009–2012) vs. 54.3% (2018–2022)).

Conclusions In this cohort, 50.4% of true BE-LGD was endoscopically visible, with increased recognition endoscopically over time and a higher rate of visible LGD detected at a BRU when compared with the community. BRU assessment of BE-LGD remains crucial; however, improving endoscopy surveillance quality in the community is equally important.

Keywords

Barrett's and adenocarcinoma - Endoscopy Upper GI Tract - Diagnosis and imaging (inc chromoendoscopy, NBI, iSCAN, FICE, CLE) - Endoscopic resection (ESD, EMRc, ...) - Quality and logistical aspects - Image and data processing, documentatiton

• References

• 1 Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of oesophageal adenocarcinoma. Gastroenterology 2015; 149: 302-17.e1
• 2 Solanky D, Krishnamoorthi R, Crews N. et al. Barrett oesophagus length, nodularity, and low-grade dysplasia are predictive of progression to oesophageal adenocarcinoma. J Clin Gastroenterol 2019; 53: 361-365
• 3 Hameeteman W, Tytgat GN, Houthoff HJ. et al. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1 249-1256
• 4 Wani S, Muthusamy VR, Shaheen NJ. et al. Development of quality indicators for endoscopic eradication therapies in Barrett's oesophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's oesophagus) Consortium. Gastrointest Endosc 2017; 86: 1-17.e3
• 5 Duits LC, Phoa KN, Curvers WL. et al. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 2015; 64: 700-706
• 6 Vennalaganti P, Kanakadandi V, Goldblum J. et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s oesophagus. Gastroenterology 2017; 152: 564-570
• 7 Nieuwenhuis EA, van Munster SN, Curvers WL. et al. Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's oesophagus diagnosed in community hospitals. Endoscopy 2022; 54: 936-944
• 8 Tsoi EH, Mahindra P, Cameron G. et al. Barrett's oesophagus with low-grade dysplasia: high rate of upstaging at Barrett's oesophagus referral units suggests progression rates may be overestimated. Gastrointest Endosc 2021; 94: 902-908
• 9 Hussein M, Sehgal V, Sami S. et al. The natural history of low-grade dysplasia in Barrett's oesophagus and risk factors for progression. JGH Open 2021; 5: 1019-1025
• 10 Tsoi EH, Fehily S, Williams R. et al. Diffuse endoscopically visible, predominantly low-grade dysplasia in Barrett's oesophagus (with video). Endosc Int Open 2019; 7: E1742-E1747
• 11 Qumseya B, Sultan S. ASGE Standards Of Practice Committee. et al. ASGE guideline on screening and surveillance of Barrett's oesophagus. Gastrointest Endosc 2019; 90: 335-359.e2
• 12 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett's oesophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
• 13 Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005; 37: 570-578
• 14 Yang LS, Holt BA, Williams R. et al. Endoscopic features of buried Barrett's mucosa. Gastrointest Endosc 2021; 94: 14-21
• 15 Whiteman DC, Appleyard M, Bahin FF. et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's oesophagus and early oesophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-820
• 16 Sharma P, Dent J, Armstrong D. et al. The development and validation of an endoscopic grading system for Barrett's oesophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
• 17 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
• 18 Fitzgerald RC, di Pietro M, Ragunath K. et al. British society of gastroenterology. British society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42
• 19 Curvers WL, ten Kate FJ, Krishnadath KK. et al. Low-grade dysplasia in Barrett's oesophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530
• 20 Qumseya BJ, Wani S, Gendy S. et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 849-865
• 21 Schölvinck DW, van der Meulen K, Bergman JJGHM. et al. Detection of lesions in dysplastic Barrett's oesophagus by community and expert endoscopists. Endoscopy 2017; 49: 113-120
• 22 Cameron GR, Jayasekera CS, Williams R. et al. Detection and staging of oesophageal cancers within Barrett's oesophagus is improved by assessment in specialized Barrett's units. Gastrointest Endosc 2014; 80: 971-83.e1
• 23 Levink IJM, Tearney GJ, Erler NS. et al. Barrett's epithelial thickness, assessed by volumetric laser endomicroscopy, is associated with response to radiofrequency ablation. Clin Gastroenterol Hepatol 2021; 19: 1160-1169.e2
• 24 Pech O, Gossner L, Manner H. et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593